Venture • Life Science

GIMV Invests In Hypnion

On January 1, 2000, private equity firm GIMV invested in life science company Hypnion

Investment Context
  • This is GIMV’s 2nd transaction in the Life Science sector.
  • This is GIMV’s 2nd transaction in the United States.
  • This is GIMV’s 1st transaction in Massachusetts.
Investment Fate
  • Hypnion was sold to a publicly-traded strategic buyer in 2007 for 315M USD.

Explore All 557 Venture Life Science Deals - Search the Database Free


Investment Summary

Date January 1, 2000
Target Hypnion
Sector Life Science
Investor(s) GIMV
Deal Type Venture

Target Company

Hypnion

Lexington, Massachusetts, United States
Hypnion is a biotech company that researches and develops sleep disorder therapies. The company was set up in 2000 by a number of authoritative names in the field of sleep disorder research. It owns the rights to SCORE- 2004™, a method for testing drugs used to treat sleep and waking disorders, which allows quick and accurate measurement of the impact of a particular drug on a broad range of sleep and waking parameters.
Explore More Deals

Browse All 215,130 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Investor Overview 1

Investor

GIMV

Antwerp, Belgium

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1980
PE ASSETS 2.0B EUR
Size Large
Type Sector Agnostic
DESCRIPTION

GIMV is a Belgium based public investment company focused on private equity and venture capital investments in tech-based businesses. GIMV's private equity practice operates through its Corporate Investment unit and targets management buyouts, buy-ins, and growth capital financings of companies with annual sales between EUR15 and EUR150 million. For buyout opportunities GIMV generally takes a majority stake in businesses and for growth capital needs, GIMV takes a minority position. GIMV does not invest in publicly held companies or turnaround situations. GIMV's geographic focus is within Belgium, Netherlands, Germany, and France. GIMV also invests in Russia through Eagle Capital Partners, a partnership with KBC Private Equity. GIMV was formed in 1980 and is headquartered in Antwerp with additional offices in The Hague, Frankfurt, Munich, and Paris.


Deal Context for Investor #
Overall 7 of 170
Sector: Life Science 2 of 24
Type: Venture 1 of 39
State: Massachusetts 1 of 3
Country: United States 2 of 7
Year: 2000 3 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2000-01-01 Dujardin Foods NV

Ardooie-Koolskamp, Belgium

Dujardin Foods NV is a producer and supplier of fresh frozen vegetables, aromatic herbs, ingredients, and ready-to-eat meals.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2000-02-01 Impression

Belgium

Impression Group is Europe's largest printing group, specializing in large-format printing like advertising posters and point of sale promotion material. They also provide vehicle graphics and building / scaffold wraps.

Buy -